UCB Bets on Candid Therapeutics to Boost Immunology Pipeline with T-cell Engagers
UCB has entered into a definitive agreement to acquire Candid Therapeutics, strengthening its immunology pipeline and advancing its capabilities in next-generation biologics, particularly T-cell engagers (TCEs). The deal aligns with UCB’s strategy to expand innovative treatments for severe immune-mediated diseases and reinforce its position in immunology.
A key component of the acquisition is cizutamig, Candid’s lead investigational asset. This bispecific antibody targets B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, enabling targeted immune responses to elim...
